Trial of Nivolumab and BMS-813160 with or without GVAX for Locally Advanced Pancreatic Cancer

Inclusion Criteria

• Must be 18 years or older.
• Have a confirmed diagnosis of locally advanced pancreatic cancer that cannot be removed by surgery.
• Agree to have a biopsy if needed for the study.
• Agree to have imaging tests done if needed for the study.
• Have not received any prior treatment for this type of cancer.
• Be in good overall health, with a performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Have a life expectancy of more than 3 months.
• Be able to swallow pills or capsules.
• Have adequate organ function based on specific lab tests.
• Be eligible to receive a specific type of chemotherapy called FOLFIRINOX.
• Agree to receive radiation therapy at Johns Hopkins Hospital.
• Agree to have a biopsy of the pancreatic cancer if not eligible for surgery.
• Use effective birth control while participating in the study.
• Understand and agree to sign a consent form.

Exclusion Criteria

• Have received a different type of chemotherapy for pancreatic cancer.
• Have received any cancer vaccines or biologics within 28 days before starting the study.
• Have had previous treatment with certain immunotherapy drugs.
• Have had an organ or tissue transplant.
• Are currently in another cancer treatment study.
• Are using immunosuppressive medications within 14 days before starting the study.
• Have received any vaccine within 14 days before starting the study.
• Are using growth factors within 14 days before starting the study.
• Have a history of autoimmune disease, except for thyroid disease.
• Have a history of lung inflammation or current lung issues.
• Have low oxygen levels in the blood.
• Require home oxygen.
• Have uncontrolled health issues like recent heart attack or stroke, severe infection, heart failure, or mental health issues.
• Have certain heart conditions based on an ECG test.
• Have an active infection needing treatment.
• Have HIV or hepatitis B or C.
• Have another type of cancer, except for certain non-threatening cancers.
• Have a gastrointestinal disease affecting medication absorption.
• Have had gastrointestinal surgery affecting medication absorption.
• Cannot take oral medication.
• Cannot have blood drawn.
• Have had surgery within 28 days before starting the study.
• Have used certain medications affecting the study drugs within 28 days before starting the study.
• Have fluid buildup in the abdomen needing treatment.
• Have cancer invading the stomach or intestines.
• Have an allergy to monoclonal antibodies.
• Have an allergy to study drugs or their components.
• Are pregnant or breastfeeding.
• Are unable or unwilling to follow the study schedule.